Cholera vaccine candidate 638: Intranasal immunogenicity and expression of a foreign antigen from the pulmonary pathogen Coccidioides immitis

Vaccine

Volumn 21, Issue 32, 2003, Pages 4715-4721

  Silva, Anisia J ^a   Mohan, Archana ^b   Benitez, Jorge A ^a  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

^b CALIFORNIA STATE UNIVERSITY   (United States)

Author keywords

Antigen 2; Cholera vaccines; Coccidioides immitis; Coccidioidomycosis; Proline rich antigen; Valley fever; Vibrio cholerae

Indexed keywords

ANTIGEN; BACTERIAL TOXIN; CHOLERA TOXIN; CHOLERA VACCINE; HYBRID PROTEIN; METALLOPROTEINASE; PEPTIDE; PROLINE; RECOMBINANT PROTEIN; ZINC;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; BACTERIAL GENETICS; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; COCCIDIOIDES IMMITIS; COCCIDIOIDOMYCOSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOPLASM; ESCHERICHIA COLI; FEMALE; GENE DELETION; GENETIC CODE; IMMUNIZATION; IMMUNOGENICITY; INOCULATION; LUNG INFECTION; MOUSE; MOUSE STRAIN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROPHAGE; PROTEIN EXPRESSION;

EID: 0142258053     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00515-2     Document Type: Article

References (19)

1. Chen I., Finn T.M., Yanqing L., Guoming Q., Rappuoli R., Pizza M. A recombinant live attenuated strain of Vibrio cholerae induces immunity against tetanus toxin and Bordetella pertussis tracheal colonization factor. Infect. Immun. 66:1998;1648-1653.
2. Levine MM, Tacket CO. Recombinant live cholera vaccines. In: Wachsmuth IK, Blake PA, Olsvik Ö (Eds.), Vibrio cholerae and cholera: molecular to global perspective. Washington, DC: American Society of Microbiology; 1994. p. 395-413.
3. Robert A., Silva A., Benítez J.A., Rodriguez B.L., Fando R., Campos J.et al. Tagging a Vibrio cholerae El Tor candidate vaccine strain by disruption of its hemagglutinin/protease gene using a novel reporter gene: Clostridium thermocellum endoglucanase A. Vaccine. 14:1996;1517-1522.
4. Benítez J.A., García L., Silva A., García H., Fando R., Cedré B.et al. Preliminary assessment of the safety and immunogenicity of a new CTXΦ-negative, hemagglutinin/protease-defective El Tor strain as a cholera vaccine candidate. Infect. Immun. 67:1999;539-545.
5. Pappagianis D. Seeking a vaccine against Coccidioides immitis and serologic studies: expectations and realities. Fungal Genet. Biol. 32:2001;1-9.
6. Dugger K.O., Villareal K.M., Nguen A., Zimmerman C.R., Law J.H., Galgiani J.N. Cloning and sequence analysis of the cDNA for a protein from Coccidioides immitis with immunogenic potential. Biochem. Biophys. Res. Commun. 218:1996;485-489.
7. Zhu Y., Chunmu Y., Magee M., Cox R.R. Coccidioides immitis antigen 2: analysis of gene and protein. Gene. 181:1996;121-125.
8. Galgiani J.N., Sun S.H., Dugger K.O., Ampel N.M., Grace G.C., Harrison J.et al. An arthroconidial-spherule antigen of Coccidioides immitis: differential expression during in vitro fungal development and evidence for humoral response in humans after infection or vaccination. Infect. Immun. 60:1992;2627-2635.
9. Kirkland T.N., Finley F., Osborn K.J., Galgiani J.N. Evaluation of the proline-rich antigen of Coccidioides immitis as a vaccine candidate in mice. Infect. Immun. 66:1998;3519-3522.
10. Abuodeh R.O., Shubitz L., Siegel E., Snyder S., Peng T., Osborn K.J.et al. Resistance to Coccidioides immitis in mice after immunization with recombinant protein or a DNA vaccine of a proline-rich antigen. Infect. Immun. 67:1999;2935-2940.
11. Shubitz L., Peng T., Perrill R., Simons J., Orsborn K., Galgiani J.N. Protection of mice against Coccidioides immitis intranasal infection by vaccination with recombinant antigen 2/PRA. Infect. Immun. 70:2002;3287-3289.
12. Sánchez J., Johansson S., Löwenadler B., Svennerholm A.M., Holmgren J. Recombinant cholera toxin B subunit and gene fusion proteins for oral vaccination. Res. Microbiol. 141:1990;971-979.
13. Marcus H., Ketley J.M., Kaper J.B., Holmes R.K. Effect of DNAse production, plasmid size and restriction barrier on transformation of Vibrio cholerae by electroporation and osmotic shock. FEMS Microbiol. Lett. 68:1990;149-154.
14. Qu Z.H., Boesman-Finkelstein M., Finkelstein R.A. Urea-induced release of heat-labile enterotoxin from Escherichia coli. J. Clin. Microbiol. 29:1991;773-777.
15. Crean T.I., John M., Calderwood S.B., Ryan E.T. Optimizing the germfree mouse model for in vivo evaluation of oral Vibrio cholera vaccine and vector strains. Infect. Immun. 68:2000;977-981.
16. Levine M.M., Kaper J.B. Live oral vaccines against cholera: an update. Vaccine. 11:1993;207-212.
17. Fullner K.J., Boucher J.C., Hanes M.A., Haines G.K., Meehan B.M., Walchle C.et al. The contribution of accessory toxins of Vibrio cholerae O1 El Tor to the proinflammatory response in a murine pulmonary cholera model. J. Exp. Med. 195:2002;1455-1462.
18. van Ginkel F.W., Nguyen H.H., McGhee J.R. Vaccines for mucosal immunity to combat emerging infectious disease. Emer. Infect. Dis. 6:2000;123-132.
19. Eko F.O., Lubitz W., Mcmillan L., Ramey K., Moore T.T., Ananaba G.A. Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis. Vaccine. 21:2003;1694-1703.